Highest-materiality recent filing
AbbVie to acquire Apogee Therapeutics for $10.9B; adds zumilokibart pipeline
Total equity value ~$10.9 billion, AbbVie to pay $135.11 per share in cash for all outstanding shares.
AbbVie Q1 adjusted EPS $2.65 (+7.7%), revenue $15.0B (+12.4%); raises FY2026 guidance
GAAP diluted EPS $0.39, down 45.8%; adjusted EPS $2.65, up 7.7%, with $0.41 IPR&D headwind.
AbbVie records $744M IPR&D expense in Q1; cuts adjusted EPS guidance by $0.41
Q1 2026 includes $744M pre-tax acquired IPR&D and milestones expense, reducing EPS by $0.41.
AbbVie closes $7.75B debt offering across seven tranches (2028-2066)
Completed public offering of $750M floating rate notes due 2028 and $7B in fixed rate notes (3.775% to 5.650%) maturing 2028-2066.
AbbVie Q4 revenue $16.6B (+10%); FY2025 adj EPS $10.00; guides FY2026 adj EPS $14.37-$14.57
FY2025 revenue $61.160B (+8.6% reported); GAAP diluted EPS $2.36; adjusted diluted EPS $10.00 (-1.2% YoY).
AbbVie cuts Q4 2025 adjusted EPS guidance by $0.71 on $1.265B IPR&D charge
Q4 2025 adjusted EPS guidance revised to $2.61-$2.65 from prior $3.32-$3.36.
AbbVie Q3 adjusted EPS $1.86 (down 38%), revenue up 9.1%; raises FY25 guidance; dividend up 5.5%
GAAP diluted EPS $0.10 (down 88.6%); adjusted diluted EPS $1.86 (down 38%); includes $1.50/share unfavorable impact from acquired IPR&D.
AbbVie cuts FY 2025 adjusted EPS guidance to $10.38-$10.58 on $2.68B Q3 IPR&D charge
Q3 2025 acquired IPR&D and milestones expense of $2.68B reduces adjusted EPS by $1.50.
AbbVie settles RINVOQ patent litigation; no generic entry until at least April 2037
Settled litigation with all generic manufacturers over RINVOQ (upadacitinib) ANDAs.
AbbVie Q2 adjusted EPS $2.97 (+12.1%); raises FY 2025 guidance to $11.88-$12.08
Q2 GAAP EPS $0.52 (down 32.5%); adjusted EPS $2.97 (+12.1%); revenue $15.423B (+6.6%).
AbbVie expects Q2 2025 acquired IPR&D expense of $823M, lowers adjusted EPS guide
Acquired IPR&D and milestones expense of $823M pre-tax in Q2 2025 reduces GAAP and adjusted EPS by $0.42.
AbbVie Q1 adj EPS $2.46 (+6.5%), revenue $13.34B (+8.4%); raises FY EPS guidance to $12.09-$12.29
Q1 GAAP EPS $0.72 (down 6.5%), adjusted EPS $2.46 (up 6.5%); revenue $13.34B (+8.4% reported).
AbbVie revises FY 2025 adj. EPS guidance down $0.13 on $248M IPR&D charge
Q1 2025 includes $248M pre-tax acquired IPR&D and milestones expense.
AbbVie enters $3.0 billion revolving credit facility maturing in 2030
On January 30, 2025, AbbVie entered a $3.0 billion unsecured revolving credit agreement with JPMorgan Chase as agent.
Q4 revenue $15.102B (+5.6% reported); full-year revenue $56.334B (+3.7% reported).
AbbVie to record $3.5B impairment on emraclidine after Phase 2 schizophrenia failure
Non-cash after-tax impairment charge of ~$3.5B on emraclidine intangible asset from Cerevel acquisition.
AbbVie reports $1.574B Q4 IPR&D charge, cuts adjusted EPS guidance by $0.88
Expected Q4 2024 acquired IPR&D and milestones expense of $1,574M pre-tax, $0.88 per share impact.
Adjusted diluted EPS $3.00, up 1.7% YoY; GAAP EPS $0.88, down 12.0%.
AbbVie Q2 adj EPS $2.65, revenue $14.46B; raises FY2024 adj EPS guidance to $10.71-$10.91
Q2 GAAP EPS $0.77 (down 32.5% YoY); adjusted EPS $2.65 (down 8.9% YoY), including $0.52 IPR&D impact.
AbbVie lowers 2024 adjusted EPS guidance to $10.61-$10.81 on $937M IPR&D charge
Preliminary Q2 2024 acquired IPR&D and milestones expense of $937 million pre-tax.
AbbVie Q1 adjusted EPS $2.31 (-6.1% YoY); raises 2024 guidance; CEO succession
Q1 revenue $12.31B (+0.7% reported, +1.6% operational); GAAP EPS $0.77, adjusted EPS $2.31.
AbbVie updates 2024 EPS guidance after incurring $164M IPR&D expense in Q1
Acquired IPR&D and milestones expense of $164M pre-tax ($0.08 per share) recorded in Q1 2024.
AbbVie issues $15B in senior notes across 7 tranches to fund acquisitions and repay debt
Issued $15.0B aggregate principal of senior notes maturing 2027-2064 with coupons from 4.800% to 5.500%.
AbbVie names Robert Michael as CEO effective July 1; Gonzalez to executive chairman
Robert A. Michael, current president & COO, will become CEO on July 1, 2024.
Acquired all outstanding ImmunoGen shares for $31.26 each; ImmunoGen ceases trading on NASDAQ.
AbbVie Q4 adj. EPS $2.79, revenue $14.3B; FY2024 adj. EPS guidance $11.05-$11.25
Full-year 2023 GAAP EPS $2.72 (-59%); adjusted EPS $11.11 (-19.3%); revenue $54.3B (-6.4%).
AbbVie to acquire Cerevel Therapeutics for $45/share (~$8.7B equity value)
Transaction valued at $45.00 per Cerevel share, total equity ~$8.7B; approved by both boards.
AbbVie to acquire ImmunoGen for $31.26/share ($10.1B total) – adds ovarian cancer therapy ELAHERE
Transaction valued at $31.26 per share in cash, total equity value approx $10.1B.
AbbVie Q3 adj EPS $2.95 (down 19.4%); raises FY23 and FY24 guidance; dividend up 4.7%
Q3 GAAP diluted EPS $1.00 (down 54.8% YoY); adjusted diluted EPS $2.95 (down 19.4%); net rev $13.93B (down 6.0%).
AbbVie Q2 adj EPS $2.91 (-13.6%), rev $13.865B (-4.9%); raises FY adj EPS guidance to $10.90-$11.10
GAAP diluted EPS $1.14 (+123.5% YoY); adjusted diluted EPS $2.91 (-13.6% YoY); includes $0.15 IPR&D impact.
AbbVie Q1 revenue $12.2B down 9.7%; GAAP EPS $0.13, adj. EPS $2.46; raises FY guidance
Q1 net revenues $12.225B, down 9.7% reported / 8.3% operational; GAAP diluted EPS $0.13 (down 94.8%), adj. diluted EPS $2.46 (down 22.2%).
AbbVie lowers 2023 adjusted EPS guidance by $0.08 on $150M Q1 IPR&D expense
Q1 2023 acquired IPR&D and milestones expense of $150M pre-tax reduces GAAP and adjusted EPS by $0.08.
AbbVie reports FY 2022 adjusted EPS $13.77 (+16.4% YoY); guides FY 2023 adjusted EPS $10.70-$11.10
FY 2022 net revenues $58.054B (+3.3% reported, +5.1% operational); Q4 net revenues $15.121B (+1.6% reported, +3.8% operational).
The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.
The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.
Glenn F. Tilton informed the Company of his decision to retire as a director, effective July 1, 2025.
Mr. Gonzalez, who has served as Chairman since the Company’s formation in 2013, will retire from the Board, effective July 1, 2025.
On February 13, 2025, the Board of Directors (the “Board”) of AbbVie Inc. (the “Company”) unanimously elected Robert A. Michael to succeed Richard A. Gonzalez as the Company’s Chairman, effective July 1, 2025.
Mr. Gonzalez will become Executive Chairman of the Board.
selected Robert A. Michael to succeed Richard A. Gonzalez as AbbVie’s Chief Executive Officer (CEO), effective July 1, 2024
The Board also appointed Mr. Michael as a member of the Board of Directors as a Class II director, effective July 1, 2024.
Mr. Gonzalez, who has served as CEO since the company’s formation in 2013, will retire from the role of CEO and become Executive Chairman of the Board of Directors, effective July 1, 2024.
appointed Jennifer Davis as a Class II director
and Susan Quaggin as a Class III director
Effective June 29, 2023, Robert A. Michael has been appointed President and Chief Operating Officer.
Max materiality 0.90 · Median 0.68 · Most common event earnings